DNLI
Price
$14.29
Change
-$0.00 (-0.00%)
Updated
Aug 6 closing price
Capitalization
2.08B
84 days until earnings call
OCUL
Price
$12.50
Change
+$0.50 (+4.17%)
Updated
Aug 6 closing price
Capitalization
2.17B
95 days until earnings call
Interact to see
Advertisement

DNLI vs OCUL

Header iconDNLI vs OCUL Comparison
Open Charts DNLI vs OCULBanner chart's image
Denali Therapeutics
Price$14.29
Change-$0.00 (-0.00%)
Volume$911
Capitalization2.08B
Ocular Therapeutix
Price$12.50
Change+$0.50 (+4.17%)
Volume$2.97M
Capitalization2.17B
DNLI vs OCUL Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. OCUL commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (DNLI: $14.35 vs. OCUL: $12.50)
Brand notoriety: DNLI and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 143% vs. OCUL: 117%
Market capitalization -- DNLI: $2.08B vs. OCUL: $2.17B
DNLI [@Biotechnology] is valued at $2.08B. OCUL’s [@Biotechnology] market capitalization is $2.17B. The market cap for tickers in the [@Biotechnology] industry ranges from $210.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while OCUL’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 5 bearish.
  • OCUL’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both DNLI and OCUL are a bad buy in the short-term.

Price Growth

DNLI (@Biotechnology) experienced а +4.97% price change this week, while OCUL (@Biotechnology) price change was +7.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.54%. For the same industry, the average monthly price growth was +12.42%, and the average quarterly price growth was +13.42%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (-0.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.18B) and DNLI($2.09B) have the same market capitalization . OCUL YTD gains are higher at: 46.370 vs. DNLI (-29.588). OCUL has higher annual earnings (EBITDA): -176.35M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. OCUL (350M). DNLI has less debt than OCUL: DNLI (48.6M) vs OCUL (76.2M). OCUL has higher revenues than DNLI: OCUL (59.6M) vs DNLI (0).
DNLIOCULDNLI / OCUL
Capitalization2.09B2.18B96%
EBITDA-505.16M-176.35M286%
Gain YTD-29.58846.370-64%
P/E RatioN/AN/A-
Revenue059.6M-
Total Cash818M350M234%
Total Debt48.6M76.2M64%
FUNDAMENTALS RATINGS
DNLI vs OCUL: Fundamental Ratings
DNLI
OCUL
OUTLOOK RATING
1..100
7179
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
10079
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
8237
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
3430

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (57) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than DNLI’s over the last 12 months.

OCUL's Profit vs Risk Rating (79) in the Pharmaceuticals Other industry is in the same range as DNLI (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (97) in the Biotechnology industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (82) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIOCUL
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 10 days ago
80%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EEMCX13.40N/A
N/A
Columbia Emerging Markets C
FQUAX20.70N/A
N/A
AMG River Road Large Cap Value Select N
INYDX21.98N/A
N/A
Victory Pioneer Disciplined Growth Y
LMPLX57.82N/A
N/A
ClearBridge Large Cap Growth R
SSSIX25.57N/A
N/A
SouthernSun Small Cap, I